Drugmaker Elan plans string of acquisitions

Published



Elan Corp. PLC plans to pay about $338 million for a privately held, Austrian drug developer and at least $110 million for stakes in two other companies as the Irish drugmaker continues to refocus after unloading its main revenue source, an ownership stake in the multiple sclerosis drug Tysabri.

The Dublin-based company said Monday it will buy AOP Orphan Pharmaceuticals in a cash-and-stock deal valued at about 263.5 million euros. AOP, based in Vienna, focuses on rare diseases in hematology/oncology and cardiology/pulmonology. Elan also may make up milestone payments of up to 270 million euros ($346.7 million) depending on the development of potential treatments in late-stage clinical research.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.